Rhapsido Tablet
Product Images NDC 0078-1483

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Rhapsido (NDC 0078-1483). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure Of Remibrutinib (Rhapsido 01)

Chemical Structure Of Remibrutinib (Rhapsido 01)
Chemical structure of remibrutinib, showing its molecular arrangement as depicted in the image for the drug RHAPSIDO (remibrutinib) 25 mg tablet by Novartis Pharmaceuticals Corporation.*
FDA Label Image

Figure 1 Mean Change From Baseline In Weekly Itch Severity Score (iss7) And Hive Severity Score (hss7) Up To Week 24 In Remix-2 (observed Data) (Rhapsido 02)

Figure 1 Mean Change From Baseline In Weekly Itch Severity Score (iss7) And Hive Severity Score (hss7) Up To Week 24 In Remix-2 (observed Data) (Rhapsido 02)
Two line graphs comparing mean changes with standard error over 24 weeks post baseline for RHAPSIDO 25 mg tablets (twice daily) versus placebo groups. The graphs show decreases in ISS7 and HSS7 mean change values, with RHAPSIDO-treated patients exhibiting greater reductions compared to placebo. Sample sizes are 297 for RHAPSIDO and 153 for placebo in both graphs.*
FDA Label Image

Principal Display Panel Ndc 0078-1483-20 Rhapsido® (remibrutinib) Tablets 25 mg Per Tablet Swallow Tablets Whole With Water. Do Not Split, Crush, Or Chew Tablets. Rx Only 60 Tablets Novartis (Rhapsido 03)

Principal Display Panel Ndc 0078-1483-20 Rhapsido® (remibrutinib) Tablets 25 mg Per Tablet Swallow Tablets Whole With Water. Do Not Split, Crush, Or Chew Tablets. Rx Only 60 Tablets Novartis (Rhapsido 03)
The label for Rhapsido (remibrutinib) tablets, 25 mg per tablet, oral dosage form. The label indicates 60 tablets per container, with instructions to swallow whole without splitting or crushing. The product is manufactured by Novartis Pharmaceuticals Corporation. The NDC number 0078-1483-20 is shown along with storage and handling instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.